Overview

Fruquintinib DDI Study With P-gp and BCRP Substrates

Status:
Active, not recruiting
Trial end date:
2022-05-17
Target enrollment:
Participant gender:
Summary
Fruquintinib DDI Study with P-gp and BCRP Substrates
Phase:
Phase 1
Details
Lead Sponsor:
Hutchison Medipharma Limited
Treatments:
Dabigatran
Rosuvastatin Calcium